Effects of a three-month course of rosuvastatin in patients with Systemic Lupus Erythematosus
Completed
- Conditions
- Systemic lupus erythematosusMusculoskeletal Diseases
- Registration Number
- ISRCTN63412511
- Lead Sponsor
- AstraZeneca (The Netherlands)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
1. Patients with chronic, non-acute SLE
2. Greater than 18 years old, either sex
Exclusion Criteria
1. Use of statins
2. Pregnancy
3. Raised liver enzymes
4. Recent (less than three months) major surgery or myocardial infarction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measured at baseline and after three months of treatment:<br>1. Total cholesterol <br>2. Low density lipoprotein (LDL) cholesterol<br>3. C-reactive protein (CRP)<br>4. Tumour necrotising factor (TNF)
- Secondary Outcome Measures
Name Time Method Measured at baseline and after three months of treatment:<br>1. Interleukin-6 (IL6), interleukin-10 (IL10), interleukin-8 (IL8)<br>2. Complement C3 and C4q<br>3. Anti-double stranded deoxyribonucleic acid (anti-dsDNA)<br>4. Urine protein